Daklinza daclatasvir regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) expanded its review of direct-acting antivirals (DAAs) to treat chronic HCV infection to include an assessment of hepatocellular carcinoma (HCC...